These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 16923461)

  • 1. Onset and offset of platelet inhibition after high-dose clopidogrel loading and standard daily therapy measured by a point-of-care assay in healthy volunteers.
    Price MJ; Coleman JL; Steinhubl SR; Wong GB; Cannon CP; Teirstein PS
    Am J Cardiol; 2006 Sep; 98(5):681-4. PubMed ID: 16923461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dynamics of platelet functional recovery following a clopidogrel loading dose in healthy volunteers.
    Price MJ; Teirstein PS
    Am J Cardiol; 2008 Sep; 102(6):790-5. PubMed ID: 18774008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clopidogrel loading dose regimens: kinetic profile of pharmacodynamic response in healthy subjects.
    Savcic M; Hauert J; Bachmann F; Wyld PJ; Geudelin B; Cariou R
    Semin Thromb Hemost; 1999; 25 Suppl 2():15-9. PubMed ID: 10440417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administration.
    Jakubowski JA; Payne CD; Li YG; Brandt JT; Small DS; Farid NA; Salazar DE; Winters KJ
    Thromb Haemost; 2008 Feb; 99(2):409-15. PubMed ID: 18278193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose effect of clopidogrel reloading in patients already on 75-mg maintenance dose: the Reload with Clopidogrel Before Coronary Angioplasty in Subjects Treated Long Term with Dual Antiplatelet Therapy (RELOAD) study.
    Collet JP; Silvain J; Landivier A; Tanguy ML; Cayla G; Bellemain A; Vignolles N; Gallier S; Beygui F; Pena A; Montalescot G
    Circulation; 2008 Sep; 118(12):1225-33. PubMed ID: 18765393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial.
    Wiviott SD; Trenk D; Frelinger AL; O'Donoghue M; Neumann FJ; Michelson AD; Angiolillo DJ; Hod H; Montalescot G; Miller DL; Jakubowski JA; Cairns R; Murphy SA; McCabe CH; Antman EM; Braunwald E;
    Circulation; 2007 Dec; 116(25):2923-32. PubMed ID: 18056526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional effects of high clopidogrel maintenance dosing in patients with inadequate platelet inhibition on standard dose treatment.
    Angiolillo DJ; Costa MA; Shoemaker SB; Desai B; Bernardo E; Suzuki Y; Charlton RK; Zenni MM; Guzman LA; Bass TA
    Am J Cardiol; 2008 Feb; 101(4):440-5. PubMed ID: 18312754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study.
    Angiolillo DJ; Shoemaker SB; Desai B; Yuan H; Charlton RK; Bernardo E; Zenni MM; Guzman LA; Bass TA; Costa MA
    Circulation; 2007 Feb; 115(6):708-16. PubMed ID: 17261652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer: the VERIfy Thrombosis risk ASsessment (VERITAS) study.
    Malinin A; Pokov A; Spergling M; Defranco A; Schwartz K; Schwartz D; Mahmud E; Atar D; Serebruany V
    Thromb Res; 2007; 119(3):277-84. PubMed ID: 16563469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional impact of high clopidogrel maintenance dosing in patients undergoing elective percutaneous coronary interventions. Results of a randomized study.
    Angiolillo DJ; Bernardo E; Palazuelos J; Desai B; Weisberg I; Alfonso F; Guzman LA; Hernández-Antolin R; Zenni MZ; Macaya C; Fernandez-Ortiz A; Bass TA
    Thromb Haemost; 2008 Jan; 99(1):161-8. PubMed ID: 18217149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of speed of onset of platelet inhibition after loading doses of clopidogrel versus prasugrel in healthy volunteers and correlation with responder status.
    Weerakkody GJ; Jakubowski JA; Brandt JT; Farid NA; Payne CD; Zhu J; Warner MR; Naganuma H; Winters KJ
    Am J Cardiol; 2007 Jul; 100(2):331-6. PubMed ID: 17631093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days.
    von Beckerath N; Kastrati A; Wieczorek A; Pogatsa-Murray G; Sibbing D; Graf I; Schömig A
    Eur Heart J; 2007 Aug; 28(15):1814-9. PubMed ID: 17272357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repeated-dose pharmacodynamics of clopidogrel in healthy subjects.
    Thebault JJ; Kieffer G; Lowe GD; Nimmo WS; Cariou R
    Semin Thromb Hemost; 1999; 25 Suppl 2():9-14. PubMed ID: 10440416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of higher clopidogrel loading and maintenance dose to standard dose on platelet function and outcomes after percutaneous coronary intervention using drug-eluting stents.
    Abuzahra M; Pillai M; Caldera A; Hartley WB; Gonzalez R; Bobek J; Dokainish H; Lakkis N
    Am J Cardiol; 2008 Aug; 102(4):401-3. PubMed ID: 18678295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry.
    Jakubowski JA; Payne CD; Li YG; Farid NA; Brandt JT; Small DS; Salazar DE; Winters KJ
    Thromb Haemost; 2008 Jan; 99(1):215-22. PubMed ID: 18217157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of timing of clopidogrel administration on 30-day clinical outcomes: 300-mg loading dose immediately after coronary stenting versus pretreatment 6 to 24 hours before stenting in a large unselected patient cohort.
    Szük T; Gyöngyösi M; Homorodi N; Kristóf E; Király C; Edes IF; Facskó A; Pavo N; Sodeck G; Strehblow C; Farhan S; Maurer G; Glogar D; Domanovits H; Huber K; Edes I
    Am Heart J; 2007 Feb; 153(2):289-95. PubMed ID: 17239691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries.
    Motovska Z; Kala P
    Clin Ther; 2008; 30 Pt 2():2191-202. PubMed ID: 19281914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial.
    Montalescot G; Sideris G; Meuleman C; Bal-dit-Sollier C; Lellouche N; Steg PG; Slama M; Milleron O; Collet JP; Henry P; Beygui F; Drouet L;
    J Am Coll Cardiol; 2006 Sep; 48(5):931-8. PubMed ID: 16949482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of high loading and maintenance dose of clopidogrel within the first 15 days after percutaneous coronary intervention on patient outcome.
    Lemesle G; Delhaye C; Sudre A; Broucqsault D; Rosey G; Bauters C; Lablanche JM
    Am Heart J; 2009 Feb; 157(2):375-82. PubMed ID: 19185648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes.
    Storey RF; Husted S; Harrington RA; Heptinstall S; Wilcox RG; Peters G; Wickens M; Emanuelsson H; Gurbel P; Grande P; Cannon CP
    J Am Coll Cardiol; 2007 Nov; 50(19):1852-6. PubMed ID: 17980251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.